J A Johnson1, S L Bowker, K Richardson, C A Marra. 1. Department of Public Health Sciences, University of Alberta, 2-040 Li Ka Shing Center, Edmonton, AB, Canada. jeff.johnson@ualberta.ca
Abstract
AIMS/HYPOTHESIS: Despite the vast body of epidemiological literature on the risk of cancer in people with diabetes, few studies have examined the pattern of cancer risk during different time windows following diabetes onset. The objective of the study was to examine the risks of site-specific cancer in people with incident type 2 diabetes during different time windows following diabetes onset. METHODS: This was a population-based retrospective cohort study. The study period was 1 April 1994 to 31 March 2006; censoring occurred at 31 March 2006, at death or on departure from British Columbia, Canada. Using linked health databases, we identified incident cohorts with and without diabetes, who were matched by age, sex and index year. Following a minimum 2-year cancer washout period, first site-specific cancers were identified prospectively in both cohorts. RESULTS: Within 3 months following diabetes onset, participants with diabetes had significantly increased risks of colorectal, lung, liver, cervical, endometrial, ovarian, pancreatic and prostate cancers. After the initial 3-month period, the risks for colorectal (HR 1.15, 95% CI 1.05, 1.25), liver (HR 2.53, 95% CI 1.93, 3.31) and endometrial (HR 1.58, 95% CI 1.28, 1.94) cancers remained significantly elevated compared with those without diabetes. The diabetes cohort remained at increased risk of pancreatic cancer in later years, but followed a different pattern: HR 3.71 at 3 months-1 year, 2.94 at 1-2 years, 1.78 at 2-3 years and 1.65 at 3-10 years (p value for all <0.01). After an initial period of elevated risk, men with type 2 diabetes subsequently had a decreased risk of prostate cancer (HR 0.82, 95% CI 0.76, 0.88). CONCLUSIONS/ INTERPRETATION: People with type 2 diabetes are at increased risk of select cancers; this risk is particularly elevated at the time of diabetes onset, which is likely to be due to increased ascertainment.
AIMS/HYPOTHESIS: Despite the vast body of epidemiological literature on the risk of cancer in people with diabetes, few studies have examined the pattern of cancer risk during different time windows following diabetes onset. The objective of the study was to examine the risks of site-specific cancer in people with incident type 2 diabetes during different time windows following diabetes onset. METHODS: This was a population-based retrospective cohort study. The study period was 1 April 1994 to 31 March 2006; censoring occurred at 31 March 2006, at death or on departure from British Columbia, Canada. Using linked health databases, we identified incident cohorts with and without diabetes, who were matched by age, sex and index year. Following a minimum 2-year cancer washout period, first site-specific cancers were identified prospectively in both cohorts. RESULTS: Within 3 months following diabetes onset, participants with diabetes had significantly increased risks of colorectal, lung, liver, cervical, endometrial, ovarian, pancreatic and prostate cancers. After the initial 3-month period, the risks for colorectal (HR 1.15, 95% CI 1.05, 1.25), liver (HR 2.53, 95% CI 1.93, 3.31) and endometrial (HR 1.58, 95% CI 1.28, 1.94) cancers remained significantly elevated compared with those without diabetes. The diabetes cohort remained at increased risk of pancreatic cancer in later years, but followed a different pattern: HR 3.71 at 3 months-1 year, 2.94 at 1-2 years, 1.78 at 2-3 years and 1.65 at 3-10 years (p value for all <0.01). After an initial period of elevated risk, men with type 2 diabetes subsequently had a decreased risk of prostate cancer (HR 0.82, 95% CI 0.76, 0.88). CONCLUSIONS/ INTERPRETATION:People with type 2 diabetes are at increased risk of select cancers; this risk is particularly elevated at the time of diabetes onset, which is likely to be due to increased ascertainment.
Authors: Louise Pilote; Christine A Beck; Igor Karp; David Alter; Peter Austin; Jafna Cox; Karin Humphries; Cynthia Jackevicius; Hugues Richard; Jack V Tu Journal: Can J Cardiol Date: 2004-01 Impact factor: 5.223
Authors: Sebastian Schneeweiss; Colin Dormuth; Paul Grootendorst; Stephen B Soumerai; Malcolm Maclure Journal: Med Care Date: 2004-07 Impact factor: 2.983
Authors: Sebastian Schneeweiss; Philip S Wang; Jerry Avorn; Malcolm Maclure; Raia Levin; Robert J Glynn Journal: J Gen Intern Med Date: 2004-05 Impact factor: 6.473
Authors: Jung Hwan Lee; Boram Park; Jungnam Joo; Myeong-Cherl Kook; Young-Il Kim; Jong Yeul Lee; Chan Gyoo Kim; Il Ju Choi; Bang Wool Eom; Hong Man Yoon; Keun Won Ryu; Young-Woo Kim; Soo-Jeong Cho Journal: Gastric Cancer Date: 2018-04-12 Impact factor: 7.370
Authors: Phyo T Htoo; John B Buse; Mugdha Gokhale; M Alison Marquis; Virginia Pate; Til Stürmer Journal: Eur J Clin Pharmacol Date: 2016-05-10 Impact factor: 2.953
Authors: Phyo T Htoo; Til Stürmer; Michele Jonsson-Funk; Virginia Pate; Ross J Simpson; Jennifer L Lund Journal: Epidemiology Date: 2019-11 Impact factor: 4.822
Authors: Barbra A Dickerman; Johanna E Torfadottir; Unnur A Valdimarsdottir; Kathryn M Wilson; Laufey Steingrimsdottir; Thor Aspelund; Julie L Batista; Katja Fall; Edward Giovannucci; Lara G Sigurdardottir; Laufey Tryggvadottir; Vilmundur Gudnason; Sarah C Markt; Lorelei A Mucci Journal: Int J Cancer Date: 2017-11-16 Impact factor: 7.396